[
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "abemaciclib",
    "generic_name": "abemaciclib",
    "clinical_comments": "For further information, refer to individual Product Information for anticancer drugs.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01EF03",
    "atc_description": "abemaciclib"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "abemaciclib",
    "generic_name": "abemaciclib",
    "clinical_comments": "For further information, refer to individual Product Information for anticancer drugs.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01XE50",
    "atc_description": "abemaciclib"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "afatinib",
    "generic_name": "afatinib",
    "clinical_comments": "Caution should be exercised when afatinib is coadministered with PAXLOVID (refer to the afatinib Product Information).",
    "recode_effect_on_concentration_1": "<up>|afatinib",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01EB03",
    "atc_description": "afatinib"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "afatinib",
    "generic_name": "afatinib",
    "clinical_comments": "Caution should be exercised when afatinib is coadministered with PAXLOVID (refer to the afatinib Product Information).",
    "recode_effect_on_concentration_1": "<up>|afatinib",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01XE13",
    "atc_description": "afatinib"
  },
  {
    "drug _class": "Alpha 1-adrenoreceptor antagonist",
    "drugs_within_class": "alfuzosin",
    "generic_name": "alfuzosin",
    "clinical_comments": "Co-administration contraindicated due to potential hypotension (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|alfuzosin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "G04CA01",
    "atc_description": "alfuzosin"
  },
  {
    "drug _class": "Sedative/hypnotics",
    "drugs_within_class": "alprazolam",
    "generic_name": "alprazolam",
    "clinical_comments": "Caution is warranted during the first several days when alprazolam is co-administered with ritonavir before induction of alprazolam metabolism develops.",
    "recode_effect_on_concentration_1": "<up>|alprazolam",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N05BA12",
    "atc_description": "alprazolam"
  },
  {
    "drug _class": "Antiarrhythmics",
    "drugs_within_class": "amiodarone",
    "generic_name": "amiodarone",
    "clinical_comments": "Co-administration contraindicated due to potential for cardiac arrhythmias (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|antiarrhythmic",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "C01BD01",
    "atc_description": "amiodarone"
  },
  {
    "drug _class": "Antidepressants",
    "drugs_within_class": "amitriptyline",
    "generic_name": "amitriptyline",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.",
    "recode_effect_on_concentration_1": "<up>|amitriptyline",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N06AA09",
    "atc_description": "amitriptyline"
  },
  {
    "drug _class": "Calcium channel blockers",
    "drugs_within_class": "amlodipine",
    "generic_name": "amlodipine",
    "clinical_comments": "Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PAXLOVID.  If co-administered, refer to individual Product Information for calcium channel blocker for further information.",
    "recode_effect_on_concentration_1": "<up>|calcium channel blocker",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C08CA01",
    "atc_description": "amlodipine"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "apalutamide",
    "generic_name": "apalutamide",
    "clinical_comments": "Co-administration contraindicated due to potential loss of virologic response and possible resistance (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<down>|nirmatrelvir/ritonavir",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Resistance inducing",
    "atc_level": "L02BB05",
    "atc_description": "apalutamide"
  },
  {
    "drug _class": "Anti-HIV protease inhibitors",
    "drugs_within_class": "atazanavir",
    "generic_name": "atazanavir",
    "clinical_comments": "For further information, refer to the respective protease inhibitors' Product Information.",
    "recode_effect_on_concentration_1": "<up>|protease Inhibitor",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AE08",
    "atc_description": "atazanavir"
  },
  {
    "drug _class": "HMG-CoA reductase inhibitors",
    "drugs_within_class": "atorvastatin",
    "generic_name": "atorvastatin",
    "clinical_comments": "Consider temporary discontinuation of atorvastatin and rosuvastatin during treatment with PAXLOVID.",
    "recode_effect_on_concentration_1": "<up>|atorvastatin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C10AA05",
    "atc_description": "atorvastatin"
  },
  {
    "drug _class": "Anti-infective",
    "drugs_within_class": "atovaquone",
    "generic_name": "atovaquone",
    "clinical_comments": "Careful monitoring of serum levels or therapeutic effects is recommended when atovaquone is co-administered with ritonavir.",
    "recode_effect_on_concentration_1": "<down>|atovaquone",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "P01AX06",
    "atc_description": "atovaquone"
  },
  {
    "drug _class": "PDE5 inhibitor",
    "drugs_within_class": "avanafil",
    "generic_name": "avanafil",
    "clinical_comments": "Concomitant use with PAXLOVID is contraindicated (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|avanafil",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "G04BE10",
    "atc_description": "avanafil"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "A07EA04",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C05AA05",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D07AC01",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D07XC01",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "H02AB01",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R01AD06",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R03BA04",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S01BA06",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S01CB04",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S02BA07",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "betamethasone",
    "generic_name": "betamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S03BA03",
    "atc_description": "betamethasone"
  },
  {
    "drug _class": "Anti-HIV",
    "drugs_within_class": "bictegravir",
    "generic_name": "bictegravir",
    "clinical_comments": "For further information, refer to the respective anti-HIV drugs' Product Information.",
    "recode_effect_on_concentration_1": "<up>|bictegravir",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "",
    "atc_description": ""
  },
  {
    "drug _class": "Endothelin receptor Antagonists",
    "drugs_within_class": "bosentan",
    "generic_name": "bosentan",
    "clinical_comments": "Discontinue use of bosentan at least 36 hours prior to initiation of PAXLOVID. Refer to the bosentan Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|bosentan",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C02KX01",
    "atc_description": "bosentan"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "budesonide",
    "generic_name": "budesonide",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "A07EA06",
    "atc_description": "budesonide"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "budesonide",
    "generic_name": "budesonide",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D07AC09",
    "atc_description": "budesonide"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "budesonide",
    "generic_name": "budesonide",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R01AD05",
    "atc_description": "budesonide"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "budesonide",
    "generic_name": "budesonide",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R03BA02",
    "atc_description": "budesonide"
  },
  {
    "drug _class": "Smoking cessation",
    "drugs_within_class": "bupropion",
    "generic_name": "bupropion",
    "clinical_comments": "Monitor for an adequate clinical response to bupropion.",
    "recode_effect_on_concentration_1": "<down>|bupropion and active metabolite hydroxy-bupropion",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N06AX12",
    "atc_description": "bupropion"
  },
  {
    "drug _class": "Anticonvulsants",
    "drugs_within_class": "carbamazepine",
    "generic_name": "carbamazepine",
    "clinical_comments": "Co-administration contraindicated due to potential loss of virologic response and possible resistance (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<down>|nirmatrelvir/ritonavir",
    "recode_effect_on_concentration_2": "<up>|carbamazepine",
    "recommendation": "Resistance inducing",
    "atc_level": "N03AF01",
    "atc_description": "carbamazepine"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "ceritinib",
    "generic_name": "ceritinib",
    "clinical_comments": "For further information, refer to individual Product Information for anticancer drugs.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01ED02",
    "atc_description": "ceritinib"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "ceritinib",
    "generic_name": "ceritinib",
    "clinical_comments": "For further information, refer to individual Product Information for anticancer drugs.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01XE28",
    "atc_description": "ceritinib"
  },
  {
    "drug _class": "Immunosuppressants",
    "drugs_within_class": "ciclosporin",
    "generic_name": "ciclosporin",
    "clinical_comments": "Therapeutic concentration monitoring is recommended for immunosuppressants.",
    "recode_effect_on_concentration_1": "<up>|ciclosporin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L04AD01",
    "atc_description": "ciclosporin"
  },
  {
    "drug _class": "Immunosuppressants",
    "drugs_within_class": "ciclosporin",
    "generic_name": "ciclosporin",
    "clinical_comments": "Therapeutic concentration monitoring is recommended for immunosuppressants.",
    "recode_effect_on_concentration_1": "<up>|ciclosporin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S01XA18",
    "atc_description": "ciclosporin"
  },
  {
    "drug _class": "Anti-infective",
    "drugs_within_class": "clarithromycin",
    "generic_name": "clarithromycin",
    "clinical_comments": "Refer to the respective Product Information for anti-infective dose adjustment.",
    "recode_effect_on_concentration_1": "<up>|clarithromycin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J01FA09",
    "atc_description": "clarithromycin"
  },
  {
    "drug _class": "Antipsychotics",
    "drugs_within_class": "clozapine",
    "generic_name": "clozapine",
    "clinical_comments": "",
    "recode_effect_on_concentration_1": "<up>|clozapine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "N05AH02",
    "atc_description": "clozapine"
  },
  {
    "drug _class": "Anti-gout",
    "drugs_within_class": "colchicine",
    "generic_name": "colchicine",
    "clinical_comments": "Co-administration contraindicated due to potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|colchicine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "M04AC01",
    "atc_description": "colchicine"
  },
  {
    "drug _class": "Anticoagulants",
    "drugs_within_class": "dabigatran",
    "generic_name": "dabigatran etexilate",
    "clinical_comments": "Increased bleeding risk with dabigatran. Avoid concomitant use.",
    "recode_effect_on_concentration_1": "<up>|dabigatran",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "B01AE07",
    "atc_description": "dabigatran etexilate"
  },
  {
    "drug _class": "Anti-HIV protease inhibitors",
    "drugs_within_class": "darunavir",
    "generic_name": "darunavir",
    "clinical_comments": "Patients on ritonavir-containing HIV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or protease inhibitor adverse events with concomitant use of these protease inhibitors (see Product Information, Section 4.2 Dose and method of administration).",
    "recode_effect_on_concentration_1": "<up>|protease Inhibitor",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AE10",
    "atc_description": "darunavir"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "dasatinib",
    "generic_name": "dasatinib",
    "clinical_comments": "For further information, refer to individual Product Information for anticancer drugs.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01EA02",
    "atc_description": "dasatinib"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "dasatinib",
    "generic_name": "dasatinib",
    "clinical_comments": "For further information, refer to individual Product Information for anticancer drugs.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01XE06",
    "atc_description": "dasatinib"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "A01AC02",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C05AA09",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D07AB19",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D07XB05",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D10AA03",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "H02AB02",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R01AD03",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S01BA01",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S01CB01",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S02BA06",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "dexamethasone",
    "generic_name": "dexamethasone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S03BA01",
    "atc_description": "dexamethasone"
  },
  {
    "drug _class": "Sedative/hypnotics",
    "drugs_within_class": "diazepam",
    "generic_name": "diazepam",
    "clinical_comments": "Co-administration diazepam with ritonavir is contraindicated (see Product Information, Section 4.3 Contraindications) ",
    "recode_effect_on_concentration_1": "<up>|diazepam",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N05BA01",
    "atc_description": "diazepam"
  },
  {
    "drug _class": "Cardiac glycosides",
    "drugs_within_class": "digoxin",
    "generic_name": "digoxin",
    "clinical_comments": "Caution should be exercised when co-administering PAXLOVID with digoxin, with appropriate monitoring of serum digoxin levels. Refer to the digoxin Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|digoxin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C01AA05",
    "atc_description": "digoxin"
  },
  {
    "drug _class": "Calcium channel blockers",
    "drugs_within_class": "diltiazem",
    "generic_name": "diltiazem",
    "clinical_comments": "Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PAXLOVID.  If co-administered, refer to individual Product Information for calcium channel blocker for further information.",
    "recode_effect_on_concentration_1": "<up>|calcium channel blocker",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C05AE03",
    "atc_description": "diltiazem"
  },
  {
    "drug _class": "Calcium channel blockers",
    "drugs_within_class": "diltiazem",
    "generic_name": "diltiazem",
    "clinical_comments": "Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PAXLOVID.  If co-administered, refer to individual Product Information for calcium channel blocker for further information.",
    "recode_effect_on_concentration_1": "<up>|calcium channel blocker",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C08DB01",
    "atc_description": "diltiazem"
  },
  {
    "drug _class": "Anti-HIV",
    "drugs_within_class": "efavirenz",
    "generic_name": "efavirenz",
    "clinical_comments": "For further information, refer to the respective anti-HIV drugs' Product Information.",
    "recode_effect_on_concentration_1": "<up>|efavirenz",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AG03",
    "atc_description": "efavirenz"
  },
  {
    "drug _class": "Anti-HIV",
    "drugs_within_class": "emtricitabine",
    "generic_name": "emtricitabine",
    "clinical_comments": "For further information, refer to the respective anti-HIV drugs' Product Information.",
    "recode_effect_on_concentration_1": "<double-arrow>|emtricitabine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AF09",
    "atc_description": "emtricitabine"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "encorafenib",
    "generic_name": "encorafenib",
    "clinical_comments": "Avoid co-administration of encorafenib due to potential risk of serious adverse events such as QT interval prolongation.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01EC03",
    "atc_description": "encorafenib"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "encorafenib",
    "generic_name": "encorafenib",
    "clinical_comments": "Avoid co-administration of encorafenib due to potential risk of serious adverse events such as QT interval prolongation.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01XE46",
    "atc_description": "encorafenib"
  },
  {
    "drug _class": "Ergot derivatives",
    "drugs_within_class": "ergometrine",
    "generic_name": "ergometrine",
    "clinical_comments": "Co-administration of ergometrine with PAXLOVID is contraindicated (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|ergometrine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "G02AB03",
    "atc_description": "ergometrine"
  },
  {
    "drug _class": "Anti-infective",
    "drugs_within_class": "erythromycin",
    "generic_name": "erythromycin",
    "clinical_comments": "Refer to the respective Product Information for anti-infective dose adjustment.",
    "recode_effect_on_concentration_1": "<up>|erythromycin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D10AF02",
    "atc_description": "erythromycin"
  },
  {
    "drug _class": "Anti-infective",
    "drugs_within_class": "erythromycin",
    "generic_name": "erythromycin",
    "clinical_comments": "Refer to the respective Product Information for anti-infective dose adjustment.",
    "recode_effect_on_concentration_1": "<up>|erythromycin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J01FA01",
    "atc_description": "erythromycin"
  },
  {
    "drug _class": "Anti-infective",
    "drugs_within_class": "erythromycin",
    "generic_name": "erythromycin",
    "clinical_comments": "Refer to the respective Product Information for anti-infective dose adjustment.",
    "recode_effect_on_concentration_1": "<up>|erythromycin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S01AA17",
    "atc_description": "erythromycin"
  },
  {
    "drug _class": "Hormonal contraceptive",
    "drugs_within_class": "ethinylestradiol",
    "generic_name": "ethinylestradiol",
    "clinical_comments": "An additional, non-hormonal method of contraception should be considered.",
    "recode_effect_on_concentration_1": "<down>|ethinylestradiol",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "G03CA01",
    "atc_description": "ethinylestradiol"
  },
  {
    "drug _class": "Hormonal contraceptive",
    "drugs_within_class": "ethinylestradiol",
    "generic_name": "ethinylestradiol",
    "clinical_comments": "An additional, non-hormonal method of contraception should be considered.",
    "recode_effect_on_concentration_1": "<down>|ethinylestradiol",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L02AA03",
    "atc_description": "ethinylestradiol"
  },
  {
    "drug _class": "Immunosuppressants",
    "drugs_within_class": "everolimus",
    "generic_name": "everolimus",
    "clinical_comments": "If co-administered, refer to individual Product Information for immunosuppressant for further information.",
    "recode_effect_on_concentration_1": "<up>|everolimus",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01EG02",
    "atc_description": "everolimus"
  },
  {
    "drug _class": "Immunosuppressants",
    "drugs_within_class": "everolimus",
    "generic_name": "everolimus",
    "clinical_comments": "If co-administered, refer to individual Product Information for immunosuppressant for further information.",
    "recode_effect_on_concentration_1": "<up>|everolimus",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01XE10",
    "atc_description": "everolimus"
  },
  {
    "drug _class": "Immunosuppressants",
    "drugs_within_class": "everolimus",
    "generic_name": "everolimus",
    "clinical_comments": "If co-administered, refer to individual Product Information for immunosuppressant for further information.",
    "recode_effect_on_concentration_1": "<up>|everolimus",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L04AA18",
    "atc_description": "everolimus"
  },
  {
    "drug _class": "Calcium channel blockers",
    "drugs_within_class": "felodipine",
    "generic_name": "felodipine",
    "clinical_comments": "Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PAXLOVID.  If co-administered, refer to individual Product Information for calcium channel blocker for further information.",
    "recode_effect_on_concentration_1": "<up>|calcium channel blocker",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C08CA02",
    "atc_description": "felodipine"
  },
  {
    "drug _class": "Analgesics",
    "drugs_within_class": "fentanyl",
    "generic_name": "fentanyl",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects (including potentially fatal respiratory depression) is recommended when fentanyl is concomitantly administered with PAXLOVID.",
    "recode_effect_on_concentration_1": "<up>|fentanyl",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N01AH01",
    "atc_description": "fentanyl"
  },
  {
    "drug _class": "Analgesics",
    "drugs_within_class": "fentanyl",
    "generic_name": "fentanyl",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects (including potentially fatal respiratory depression) is recommended when fentanyl is concomitantly administered with PAXLOVID.",
    "recode_effect_on_concentration_1": "<up>|fentanyl",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N02AB03",
    "atc_description": "fentanyl"
  },
  {
    "drug _class": "Antiarrhythmics",
    "drugs_within_class": "flecainide",
    "generic_name": "flecainide",
    "clinical_comments": "Co-administration contraindicated due to potential for cardiac arrhythmias (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|antiarrhythmic",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "C01BC04",
    "atc_description": "flecainide"
  },
  {
    "drug _class": "Antidepressants",
    "drugs_within_class": "fluoxetine",
    "generic_name": "fluoxetine",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.",
    "recode_effect_on_concentration_1": "<up>|fluoxetine,",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N06AB03",
    "atc_description": "fluoxetine"
  },
  {
    "drug _class": "Anti-HIV protease inhibitors",
    "drugs_within_class": "fosamprenavir",
    "generic_name": "fosamprenavir",
    "clinical_comments": "Patients on ritonavir-containing HIV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or protease inhibitor adverse events with concomitant use of these protease inhibitors (see Product Information, Section 4.2 Dose and method of administration).",
    "recode_effect_on_concentration_1": "<up>|protease Inhibitor",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AE07",
    "atc_description": "fosamprenavir"
  },
  {
    "drug _class": "Hepatitis C direct acting antivirals",
    "drugs_within_class": "glecaprevir",
    "generic_name": "glecaprevir",
    "clinical_comments": "It is not recommended to co-administer ritonavir with glecaprevir/pibrentasvir.",
    "recode_effect_on_concentration_1": "<up>|antiviral",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AP57",
    "atc_description": "glecaprevir and pibrentasvir"
  },
  {
    "drug _class": "Antipsychotics",
    "drugs_within_class": "haloperidol",
    "generic_name": "haloperidol",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.",
    "recode_effect_on_concentration_1": "<up>|haloperidol",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N05AD01",
    "atc_description": "haloperidol"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "ibrutinib",
    "generic_name": "ibrutinib",
    "clinical_comments": "Avoid use of neratinib, venetoclax or ibrutinib.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01EL01",
    "atc_description": "ibrutinib"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "ibrutinib",
    "generic_name": "ibrutinib",
    "clinical_comments": "Avoid use of neratinib, venetoclax or ibrutinib.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01XE27",
    "atc_description": "ibrutinib"
  },
  {
    "drug _class": "Antidepressants",
    "drugs_within_class": "imipramine",
    "generic_name": "imipramine",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.",
    "recode_effect_on_concentration_1": "<up>imipramine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N06AA02",
    "atc_description": "imipramine"
  },
  {
    "drug _class": "Antifungals",
    "drugs_within_class": "isavuconazonium sulfate",
    "generic_name": "isoconazole",
    "clinical_comments": "Refer to ketoconazole, isavuconazonium sulfate, and itraconazole Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|isavuconazonium sulfate",
    "recode_effect_on_concentration_2": "<up>|nirmatrelvir/ritonavir",
    "recommendation": "Attention",
    "atc_level": "D01AC05",
    "atc_description": "isoconazole"
  },
  {
    "drug _class": "Antifungals",
    "drugs_within_class": "isavuconazonium sulfate",
    "generic_name": "isoconazole",
    "clinical_comments": "Refer to ketoconazole, isavuconazonium sulfate, and itraconazole Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|isavuconazonium sulfate",
    "recode_effect_on_concentration_2": "<up>|nirmatrelvir/ritonavir",
    "recommendation": "Attention",
    "atc_level": "G01AF07",
    "atc_description": "isoconazole"
  },
  {
    "drug _class": "Antifungals",
    "drugs_within_class": "itraconazole",
    "generic_name": "itraconazole",
    "clinical_comments": "Refer to ketoconazole, isavuconazonium sulfate, and itraconazole Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|itraconazole",
    "recode_effect_on_concentration_2": "<up>|nirmatrelvir/ritonavir",
    "recommendation": "Attention",
    "atc_level": "J02AC02",
    "atc_description": "itraconazole"
  },
  {
    "drug _class": "Antifungals",
    "drugs_within_class": "ketoconazole",
    "generic_name": "ketoconazole",
    "clinical_comments": "Refer to ketoconazole, isavuconazonium sulfate, and itraconazole Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|ketoconazole",
    "recode_effect_on_concentration_2": "<up>|nirmatrelvir/ritonavir",
    "recommendation": "Attention",
    "atc_level": "D01AC08",
    "atc_description": "ketoconazole"
  },
  {
    "drug _class": "Antifungals",
    "drugs_within_class": "ketoconazole",
    "generic_name": "ketoconazole",
    "clinical_comments": "Refer to ketoconazole, isavuconazonium sulfate, and itraconazole Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|ketoconazole",
    "recode_effect_on_concentration_2": "<up>|nirmatrelvir/ritonavir",
    "recommendation": "Attention",
    "atc_level": "G01AF11",
    "atc_description": "ketoconazole"
  },
  {
    "drug _class": "Antifungals",
    "drugs_within_class": "ketoconazole",
    "generic_name": "ketoconazole",
    "clinical_comments": "Refer to ketoconazole, isavuconazonium sulfate, and itraconazole Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|ketoconazole",
    "recode_effect_on_concentration_2": "<up>|nirmatrelvir/ritonavir",
    "recommendation": "Attention",
    "atc_level": "H02CA03",
    "atc_description": "ketoconazole"
  },
  {
    "drug _class": "Antifungals",
    "drugs_within_class": "ketoconazole",
    "generic_name": "ketoconazole",
    "clinical_comments": "Refer to ketoconazole, isavuconazonium sulfate, and itraconazole Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|ketoconazole",
    "recode_effect_on_concentration_2": "<up>|nirmatrelvir/ritonavir",
    "recommendation": "Attention",
    "atc_level": "J02AB02",
    "atc_description": "ketoconazole"
  },
  {
    "drug _class": "Anticonvulsants",
    "drugs_within_class": "lamotrigine",
    "generic_name": "lamotrigine",
    "clinical_comments": "Careful monitoring of serum levels or therapeutic effects is recommended when these medicines are co-administered with ritonavir.",
    "recode_effect_on_concentration_1": "<down>|lamotrigine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N03AX09",
    "atc_description": "lamotrigine"
  },
  {
    "drug _class": "Antiarrhythmics",
    "drugs_within_class": "lidocaine (systemic)",
    "generic_name": "lidocaine",
    "clinical_comments": "Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.",
    "recode_effect_on_concentration_1": "<up>|antiarrhythmic",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C01BB01",
    "atc_description": "lidocaine"
  },
  {
    "drug _class": "Antiarrhythmics",
    "drugs_within_class": "lidocaine (systemic)",
    "generic_name": "lidocaine",
    "clinical_comments": "Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.",
    "recode_effect_on_concentration_1": "<up>|antiarrhythmic",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C05AD01",
    "atc_description": "lidocaine"
  },
  {
    "drug _class": "Antiarrhythmics",
    "drugs_within_class": "lidocaine (systemic)",
    "generic_name": "lidocaine",
    "clinical_comments": "Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.",
    "recode_effect_on_concentration_1": "<up>|antiarrhythmic",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D04AB01",
    "atc_description": "lidocaine"
  },
  {
    "drug _class": "Antiarrhythmics",
    "drugs_within_class": "lidocaine (systemic)",
    "generic_name": "lidocaine",
    "clinical_comments": "Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.",
    "recode_effect_on_concentration_1": "<up>|antiarrhythmic",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N01BB02",
    "atc_description": "lidocaine"
  },
  {
    "drug _class": "Antiarrhythmics",
    "drugs_within_class": "lidocaine (systemic)",
    "generic_name": "lidocaine",
    "clinical_comments": "Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.",
    "recode_effect_on_concentration_1": "<up>|antiarrhythmic",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R02AD02",
    "atc_description": "lidocaine"
  },
  {
    "drug _class": "Antiarrhythmics",
    "drugs_within_class": "lidocaine (systemic)",
    "generic_name": "lidocaine",
    "clinical_comments": "Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.",
    "recode_effect_on_concentration_1": "<up>|antiarrhythmic",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S01HA07",
    "atc_description": "lidocaine"
  },
  {
    "drug _class": "Antiarrhythmics",
    "drugs_within_class": "lidocaine (systemic)",
    "generic_name": "lidocaine",
    "clinical_comments": "Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics if available.",
    "recode_effect_on_concentration_1": "<up>|antiarrhythmic",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S02DA01",
    "atc_description": "lidocaine"
  },
  {
    "drug _class": "Antihistamine",
    "drugs_within_class": "loratadine",
    "generic_name": "loratadine",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects is recommended when loratadine is co-administered with ritonavir.",
    "recode_effect_on_concentration_1": "<up>loratadine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R06AX13",
    "atc_description": "loratadine"
  },
  {
    "drug _class": "Antipsychotics",
    "drugs_within_class": "lurasidone",
    "generic_name": "lurasidone",
    "clinical_comments": "Co-administration contraindicated due to serious and/or life-threatening reactions such as cardiac arrhythmias (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|lurasidone",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "N05AE05",
    "atc_description": "lurasidone"
  },
  {
    "drug _class": "Anti-HIV",
    "drugs_within_class": "maraviroc",
    "generic_name": "maraviroc",
    "clinical_comments": "For further information, refer to the respective anti-HIV drugs' Product Information.",
    "recode_effect_on_concentration_1": "<up>|maraviroc",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AX09",
    "atc_description": "maraviroc"
  },
  {
    "drug _class": "Analgesics",
    "drugs_within_class": "methadone",
    "generic_name": "methadone",
    "clinical_comments": "Monitor methadone-maintained patients closely for evidence of withdrawal effects and adjust the methadone dose accordingly.",
    "recode_effect_on_concentration_1": "<down>|methadone",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N07BC02",
    "atc_description": "methadone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "methylprednisolone",
    "generic_name": "methylprednisolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D07AA01",
    "atc_description": "methylprednisolone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "methylprednisolone",
    "generic_name": "methylprednisolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D10AA02",
    "atc_description": "methylprednisolone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "methylprednisolone",
    "generic_name": "methylprednisolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "H02AB04",
    "atc_description": "methylprednisolone"
  },
  {
    "drug _class": "Sedative/hypnotics",
    "drugs_within_class": "midazolam (administered parenterally)",
    "generic_name": "midazolam",
    "clinical_comments": "Co-administration of midazolam (parenteral) should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. Refer to the midazolam Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|midazolam",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N05CD08",
    "atc_description": "midazolam"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "neratinib",
    "generic_name": "neratinib",
    "clinical_comments": "Avoid use of neratinib, venetoclax or ibrutinib.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "L01EH02",
    "atc_description": "neratinib"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "neratinib",
    "generic_name": "neratinib",
    "clinical_comments": "Avoid use of neratinib, venetoclax or ibrutinib.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "L01XE45",
    "atc_description": "neratinib"
  },
  {
    "drug _class": "Anti-HIV",
    "drugs_within_class": "nevirapine",
    "generic_name": "nevirapine",
    "clinical_comments": "For further information, refer to the respective anti-HIV drugs' Product Information.",
    "recode_effect_on_concentration_1": "",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AG01",
    "atc_description": "nevirapine"
  },
  {
    "drug _class": "Calcium channel blockers",
    "drugs_within_class": "nifedipine",
    "generic_name": "nifedipine",
    "clinical_comments": "Caution is warranted and clinical monitoring of patients is recommended. A dose decrease may be needed for these drugs when co-administered with PAXLOVID.  If co-administered, refer to individual Product Information for calcium channel blocker for further information.",
    "recode_effect_on_concentration_1": "<up>|calcium channel blocker",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C08CA05",
    "atc_description": "nifedipine"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "nilotinib",
    "generic_name": "nilotinib",
    "clinical_comments": "For further information, refer to individual Product Information for anticancer drugs.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01EA03",
    "atc_description": "nilotinib"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "nilotinib",
    "generic_name": "nilotinib",
    "clinical_comments": "For further information, refer to individual Product Information for anticancer drugs.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01XE08",
    "atc_description": "nilotinib"
  },
  {
    "drug _class": "Antidepressants",
    "drugs_within_class": "nortriptyline",
    "generic_name": "nortriptyline",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.",
    "recode_effect_on_concentration_1": "<up>nortriptyline",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N06AA10",
    "atc_description": "nortriptyline"
  },
  {
    "drug _class": "Antidepressants",
    "drugs_within_class": "paroxetine",
    "generic_name": "paroxetine",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.",
    "recode_effect_on_concentration_1": "<up>paroxetine, ",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N06AB05",
    "atc_description": "paroxetine"
  },
  {
    "drug _class": "Analgesics",
    "drugs_within_class": "pethidine",
    "generic_name": "pethidine",
    "clinical_comments": "Co-administration contraindicated due to potential for serious respiratory depression or haematologic abnormalities (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|pethidine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "N02AB02",
    "atc_description": "pethidine"
  },
  {
    "drug _class": "Anticonvulsants",
    "drugs_within_class": "phenobarbital",
    "generic_name": "phenobarbital",
    "clinical_comments": "Co-administration contraindicated due to potential loss of virologic response and possible resistance (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<down>|nirmatrelvir/ritonavir",
    "recode_effect_on_concentration_2": "<down>|phenobarbital",
    "recommendation": "Resistance inducing",
    "atc_level": "N03AA02",
    "atc_description": "phenobarbital"
  },
  {
    "drug _class": "Anticonvulsants",
    "drugs_within_class": "phenytoin",
    "generic_name": "phenytoin",
    "clinical_comments": "Co-administration contraindicated due to potential loss of virologic response and possible resistance (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<down>|nirmatrelvir/ritonavir",
    "recode_effect_on_concentration_2": "<down>|phenytoin",
    "recommendation": "Resistance inducing",
    "atc_level": "N03AB02",
    "atc_description": "phenytoin"
  },
  {
    "drug _class": "Hepatitis C direct acting antivirals",
    "drugs_within_class": "pibrentasvir",
    "generic_name": "pibrentasvir",
    "clinical_comments": "Refer to the sofosbuvir/velpatasvir/voxilaprevir Product Information for further information.",
    "recode_effect_on_concentration_1": "<up>|antiviral",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AP57",
    "atc_description": "glecaprevir and pibrentasvir"
  },
  {
    "drug _class": "Analgesics",
    "drugs_within_class": "piroxicam",
    "generic_name": "piroxicam",
    "clinical_comments": "Co-administration contraindicated due to potential for serious respiratory depression or haematologic abnormalities (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|piroxicam",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "M01AC01",
    "atc_description": "piroxicam"
  },
  {
    "drug _class": "Analgesics",
    "drugs_within_class": "piroxicam",
    "generic_name": "piroxicam",
    "clinical_comments": "Co-administration contraindicated due to potential for serious respiratory depression or haematologic abnormalities (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|piroxicam",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "M02AA07",
    "atc_description": "piroxicam"
  },
  {
    "drug _class": "Analgesics",
    "drugs_within_class": "piroxicam",
    "generic_name": "piroxicam",
    "clinical_comments": "Co-administration contraindicated due to potential for serious respiratory depression or haematologic abnormalities (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|piroxicam",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "S01BC06",
    "atc_description": "piroxicam"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "prednisone",
    "generic_name": "prednisone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "A07EA03",
    "atc_description": "prednisone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "prednisone",
    "generic_name": "prednisone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "H02AB07",
    "atc_description": "prednisone"
  },
  {
    "drug _class": "Antipsychotics",
    "drugs_within_class": "quetiapine",
    "generic_name": "quetiapine",
    "clinical_comments": "If co-administration is necessary, reduce quetiapine dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine Product Information for recommendations.",
    "recode_effect_on_concentration_1": "<up>|quetiapine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N05AH04",
    "atc_description": "quetiapine"
  },
  {
    "drug _class": "Anti-HIV",
    "drugs_within_class": "raltegravir",
    "generic_name": "raltegravir",
    "clinical_comments": "For further information, refer to the respective anti-HIV drugs' Product Information.",
    "recode_effect_on_concentration_1": "<down>|raltegravir",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AJ01",
    "atc_description": "raltegravir"
  },
  {
    "drug _class": "Anti-HIV",
    "drugs_within_class": "raltegravir",
    "generic_name": "raltegravir",
    "clinical_comments": "For further information, refer to the respective anti-HIV drugs' Product Information.",
    "recode_effect_on_concentration_1": "<down>|raltegravir",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AX08",
    "atc_description": "raltegravir"
  },
  {
    "drug _class": "Antianginal",
    "drugs_within_class": "ranolazine",
    "generic_name": "ranolazine",
    "clinical_comments": "Co-administration contraindicated due to potential for serious and/or life-threatening reactions (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|ranolazine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "C01EB18",
    "atc_description": "ranolazine"
  },
  {
    "drug _class": "Antimycobacterial",
    "drugs_within_class": "rifabutin",
    "generic_name": "rifabutin",
    "clinical_comments": "Refer to rifabutin Product Information for further information on rifabutin dose reduction.",
    "recode_effect_on_concentration_1": "<up>|rifabutin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J04AB04",
    "atc_description": "rifabutin"
  },
  {
    "drug _class": "Antimycobacterial",
    "drugs_within_class": "rifampicin",
    "generic_name": "rifampicin",
    "clinical_comments": "Co-administration contraindicated due to potential loss of virologic response and possible resistance. Alternate antimycobacterial drugs such as rifabutin should be considered (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<down>|nirmatrelvir/ritonavir",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Resistance inducing",
    "atc_level": "J04AB02",
    "atc_description": "rifampicin"
  },
  {
    "drug _class": "Endothelin receptor Antagonists",
    "drugs_within_class": "riociguat",
    "generic_name": "riociguat",
    "clinical_comments": "Co-administration of riociguat with PAXLOVID is not recommended (refer to riociguat Product Information).",
    "recode_effect_on_concentration_1": "<up>|riociguat",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C02KX05",
    "atc_description": "riociguat"
  },
  {
    "drug _class": "Antipsychotics",
    "drugs_within_class": "risperidone",
    "generic_name": "risperidone",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.",
    "recode_effect_on_concentration_1": "<up>|risperidone",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N05AX08",
    "atc_description": "risperidone"
  },
  {
    "drug _class": "Anticoagulants",
    "drugs_within_class": "rivaroxaban",
    "generic_name": "rivaroxaban",
    "clinical_comments": "Increased bleeding risk with rivaroxaban. Avoid concomitant use.",
    "recode_effect_on_concentration_1": "<up>|rivaroxaban",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "B01AF01",
    "atc_description": "rivaroxaban"
  },
  {
    "drug _class": "Anticoagulants",
    "drugs_within_class": "rivaroxaban",
    "generic_name": "rivaroxaban",
    "clinical_comments": "Increased bleeding risk with rivaroxaban. Avoid concomitant use.",
    "recode_effect_on_concentration_1": "<up>|rivaroxaban",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "B01AX06",
    "atc_description": "rivaroxaban"
  },
  {
    "drug _class": "HMG-CoA reductase inhibitors",
    "drugs_within_class": "rosuvastatin",
    "generic_name": "rosuvastatin",
    "clinical_comments": "Consider temporary discontinuation of atorvastatin and rosuvastatin during treatment with PAXLOVID.",
    "recode_effect_on_concentration_1": "<up>|rosuvastatin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C10AA07",
    "atc_description": "rosuvastatin"
  },
  {
    "drug _class": "Long-acting beta-adrenoceptor agonist",
    "drugs_within_class": "salmeterol",
    "generic_name": "salmeterol",
    "clinical_comments": "Co-administration is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia.",
    "recode_effect_on_concentration_1": "<up>|salmeterol",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R03AC12",
    "atc_description": "salmeterol"
  },
  {
    "drug _class": "Anti-HIV protease inhibitors",
    "drugs_within_class": "saquinavir",
    "generic_name": "saquinavir",
    "clinical_comments": "Patients on ritonavir-containing HIV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or protease inhibitor adverse events with concomitant use of these protease inhibitors (see Product Information, Section 4.2 Dose and method of administration).",
    "recode_effect_on_concentration_1": "<up>|protease Inhibitor",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AE01",
    "atc_description": "saquinavir"
  },
  {
    "drug _class": "Antidepressants",
    "drugs_within_class": "sertraline",
    "generic_name": "sertraline",
    "clinical_comments": "Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.",
    "recode_effect_on_concentration_1": "<up>|sertraline",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N06AB06",
    "atc_description": "sertraline"
  },
  {
    "drug _class": "PDE5 inhibitor",
    "drugs_within_class": "sildenafil",
    "generic_name": "sildenafil",
    "clinical_comments": "Co-administration contraindicated due to the potential for sildenafil associated adverse events, including visual abnormalities hypotension, prolonged erection, and syncope (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|sildenafil",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "G04BE03",
    "atc_description": "sildenafil"
  },
  {
    "drug _class": "HMG-CoA reductase inhibitors",
    "drugs_within_class": "simvastatin",
    "generic_name": "simvastatin",
    "clinical_comments": "Co-administration contraindicated due to potential for myopathy including rhabdomyolysis (see Product Information, Section 4.3 Contraindications). Discontinue use of simvastatin at least 12 hours prior to initiation of PAXLOVID.",
    "recode_effect_on_concentration_1": "<up>|simvastatin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "C10AA01",
    "atc_description": "simvastatin"
  },
  {
    "drug _class": "Immunosuppressants",
    "drugs_within_class": "sirolimus",
    "generic_name": "sirolimus",
    "clinical_comments": "Avoid concomitant use of sirolimus and PAXLOVID.",
    "recode_effect_on_concentration_1": "<up>|sirolimus",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L04AA10",
    "atc_description": "sirolimus"
  },
  {
    "drug _class": "Immunosuppressants",
    "drugs_within_class": "sirolimus",
    "generic_name": "sirolimus",
    "clinical_comments": "Avoid concomitant use of sirolimus and PAXLOVID.",
    "recode_effect_on_concentration_1": "<up>|sirolimus",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S01XA23",
    "atc_description": "sirolimus"
  },
  {
    "drug _class": "Hepatitis C direct acting antivirals",
    "drugs_within_class": "sofosbuvir",
    "generic_name": "sofosbuvir",
    "clinical_comments": "Patients on ritonavir-containing HCV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or HCV drug adverse events with concomitant use (see Product Information, Section 4.2 Dose and method of administration).",
    "recode_effect_on_concentration_1": "<up>|antiviral",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AP08",
    "atc_description": "sofosbuvir"
  },
  {
    "drug _class": "Hepatitis C direct acting antivirals",
    "drugs_within_class": "sofosbuvir",
    "generic_name": "sofosbuvir",
    "clinical_comments": "Patients on ritonavir-containing HCV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or HCV drug adverse events with concomitant use (see Product Information, Section 4.2 Dose and method of administration).",
    "recode_effect_on_concentration_1": "<up>|antiviral",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AX15",
    "atc_description": "sofosbuvir"
  },
  {
    "drug _class": "Herbal products",
    "drugs_within_class": "St. John's Wort (hypericum perforatum)",
    "generic_name": "St. John's Wort (hypericum perforatum)",
    "clinical_comments": "Co-administration contraindicated due to potential loss of virologic response and possible resistance (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<down>|nirmatrelvir/ritonavir",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Resistance inducing",
    "atc_level": "",
    "atc_description": ""
  },
  {
    "drug _class": "Immunosuppressants",
    "drugs_within_class": "tacrolimus",
    "generic_name": "tacrolimus",
    "clinical_comments": "Avoid use of PAXLOVID when close monitoring of immunosuppressant serum concentrations is not feasible.",
    "recode_effect_on_concentration_1": "<up>|tacrolimus",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D11AH01",
    "atc_description": "tacrolimus"
  },
  {
    "drug _class": "Immunosuppressants",
    "drugs_within_class": "tacrolimus",
    "generic_name": "tacrolimus",
    "clinical_comments": "Avoid use of PAXLOVID when close monitoring of immunosuppressant serum concentrations is not feasible.",
    "recode_effect_on_concentration_1": "<up>|tacrolimus",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L04AD02",
    "atc_description": "tacrolimus"
  },
  {
    "drug _class": "PDE5 inhibitor",
    "drugs_within_class": "tadalafil",
    "generic_name": "tadalafil",
    "clinical_comments": "Concomitant use with PAXLOVID is contraindicated (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|tadalafil",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "G04BE08",
    "atc_description": "tadalafil"
  },
  {
    "drug _class": "Anti-HIV",
    "drugs_within_class": "tenofovir",
    "generic_name": "tenofovir",
    "clinical_comments": "For further information, refer to the respective anti-HIV drugs' Product Information.",
    "recode_effect_on_concentration_1": "<up>|tenofovir",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "",
    "atc_description": "J05AF13 tenofovir alafenamide J05AF07 tenofovir disoproxil"
  },
  {
    "drug _class": "Anti-HIV protease inhibitors",
    "drugs_within_class": "tipranavir",
    "generic_name": "tipranavir",
    "clinical_comments": "Patients on ritonavir-containing HIV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or protease inhibitor adverse events with concomitant use of these protease inhibitors (see Product Information, Section 4.2 Dose and method of administration).",
    "recode_effect_on_concentration_1": "<up>|protease Inhibitor",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AE09",
    "atc_description": "tipranavir"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "triamcinolone",
    "generic_name": "triamcinolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "A01AC01",
    "atc_description": "triamcinolone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "triamcinolone",
    "generic_name": "triamcinolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "C05AA12",
    "atc_description": "triamcinolone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "triamcinolone",
    "generic_name": "triamcinolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D07AB09",
    "atc_description": "triamcinolone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "triamcinolone",
    "generic_name": "triamcinolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "D07XB02",
    "atc_description": "triamcinolone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "triamcinolone",
    "generic_name": "triamcinolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "H02AB08",
    "atc_description": "triamcinolone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "triamcinolone",
    "generic_name": "triamcinolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R01AD11",
    "atc_description": "triamcinolone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "triamcinolone",
    "generic_name": "triamcinolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "R03BA06",
    "atc_description": "triamcinolone"
  },
  {
    "drug _class": "Systemic corticosteroids",
    "drugs_within_class": "triamcinolone",
    "generic_name": "triamcinolone",
    "clinical_comments": "Increased risk for Cushing's syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone should be considered.",
    "recode_effect_on_concentration_1": "<up>|corticosteroid",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "S01BA05",
    "atc_description": "triamcinolone"
  },
  {
    "drug _class": "PDE5 inhibitor",
    "drugs_within_class": "vardenafil",
    "generic_name": "vardenafil",
    "clinical_comments": "Concomitant use with PAXLOVID is contraindicated (see Product Information, Section 4.3 Contraindications).",
    "recode_effect_on_concentration_1": "<up>|vardenafil",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "G04BE09",
    "atc_description": "vardenafil"
  },
  {
    "drug _class": "Hepatitis C direct acting antivirals",
    "drugs_within_class": "velpatasvir",
    "generic_name": "velpatasvir",
    "clinical_comments": "Patients on ritonavir-containing HCV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or HCV drug adverse events with concomitant use (see Product Information, Section 4.2 Dose and method of administration).",
    "recode_effect_on_concentration_1": "<up>|antiviral",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "",
    "atc_description": ""
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "venetoclax",
    "generic_name": "venetoclax",
    "clinical_comments": "Avoid use of neratinib, venetoclax or ibrutinib.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Contra-indicated",
    "atc_level": "L01XX52",
    "atc_description": "venetoclax"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "vinblastine",
    "generic_name": "vinblastine",
    "clinical_comments": "Co-administration of vincristine and vinblastine may lead to significant haematologic or gastrointestinal side effects.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01CA01",
    "atc_description": "vinblastine"
  },
  {
    "drug _class": "Anticancer drugs",
    "drugs_within_class": "vincristine",
    "generic_name": "vincristine",
    "clinical_comments": "Co-administration of vincristine and vinblastine may lead to significant haematologic or gastrointestinal side effects.",
    "recode_effect_on_concentration_1": "<up>|anticancer drug",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "L01CA02",
    "atc_description": "vincristine"
  },
  {
    "drug _class": "Antifungals",
    "drugs_within_class": "voriconazole",
    "generic_name": "voriconazole",
    "clinical_comments": "Avoid concomitant use of voriconazole.",
    "recode_effect_on_concentration_1": "<down>|voriconazole",
    "recode_effect_on_concentration_2": "<up>|nirmatrelvir/ritonavir",
    "recommendation": "Attention",
    "atc_level": "J02AC03",
    "atc_description": "voriconazole"
  },
  {
    "drug _class": "Hepatitis C direct acting antivirals",
    "drugs_within_class": "voxilaprevir",
    "generic_name": "voxilaprevir",
    "clinical_comments": "Patients on ritonavir-containing HCV regimens should continue their treatment as indicated. Monitor for increased PAXLOVID or HCV drug adverse events with concomitant use (see Product Information, Section 4.2 Dose and method of administration).",
    "recode_effect_on_concentration_1": "<up>|antiviral",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "",
    "atc_description": ""
  },
  {
    "drug _class": "Anticoagulants",
    "drugs_within_class": "warfarin",
    "generic_name": "warfarin",
    "clinical_comments": "Closely monitor INR if co-administration with warfarin is necessary.",
    "recode_effect_on_concentration_1": "<up><down>|warfarin",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "B01AA03",
    "atc_description": "warfarin"
  },
  {
    "drug _class": "Anti-HIV",
    "drugs_within_class": "zidovudine",
    "generic_name": "zidovudine",
    "clinical_comments": "For further information, refer to the respective anti-HIV drugs' Product Information.",
    "recode_effect_on_concentration_1": "<down>|zidovudine",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "J05AF01",
    "atc_description": "zidovudine"
  },
  {
    "drug _class": "Sleeping agent",
    "drugs_within_class": "zolpidem",
    "generic_name": "zolpidem",
    "clinical_comments": "Zolpidem and ritonavir may be co-administered with careful monitoring for excessive sedative effects.",
    "recode_effect_on_concentration_1": "<up>|zolpidem",
    "recode_effect_on_concentration_2": "",
    "recommendation": "Attention",
    "atc_level": "N05CF02",
    "atc_description": "zolpidem"
  }
]